FI66378C - Foerfarande foer framstaellning av farmakologiskt vaerdefulla 3-(3-(4-aryl-1-piperazinyl)-alkyl)-5,6,7,8-tetrahydro-s-triazolo-(4,3-a)pyridin eller -azepin - Google Patents

Foerfarande foer framstaellning av farmakologiskt vaerdefulla 3-(3-(4-aryl-1-piperazinyl)-alkyl)-5,6,7,8-tetrahydro-s-triazolo-(4,3-a)pyridin eller -azepin Download PDF

Info

Publication number
FI66378C
FI66378C FI791217A FI791217A FI66378C FI 66378 C FI66378 C FI 66378C FI 791217 A FI791217 A FI 791217A FI 791217 A FI791217 A FI 791217A FI 66378 C FI66378 C FI 66378C
Authority
FI
Finland
Prior art keywords
formula
piperazinyl
alkyl
aryl
triazolo
Prior art date
Application number
FI791217A
Other languages
English (en)
Finnish (fi)
Other versions
FI791217A (fi
FI66378B (fi
Inventor
Bruno Silvestrini
Leandro Baiocchi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of FI791217A publication Critical patent/FI791217A/fi
Application granted granted Critical
Publication of FI66378B publication Critical patent/FI66378B/fi
Publication of FI66378C publication Critical patent/FI66378C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI791217A 1978-04-18 1979-04-12 Foerfarande foer framstaellning av farmakologiskt vaerdefulla 3-(3-(4-aryl-1-piperazinyl)-alkyl)-5,6,7,8-tetrahydro-s-triazolo-(4,3-a)pyridin eller -azepin FI66378C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT22421/78A IT1094076B (it) 1978-04-18 1978-04-18 Cicloalchiltriazoli
IT2242178 1978-04-18

Publications (3)

Publication Number Publication Date
FI791217A FI791217A (fi) 1979-10-19
FI66378B FI66378B (fi) 1984-06-29
FI66378C true FI66378C (fi) 1984-10-10

Family

ID=11196066

Family Applications (1)

Application Number Title Priority Date Filing Date
FI791217A FI66378C (fi) 1978-04-18 1979-04-12 Foerfarande foer framstaellning av farmakologiskt vaerdefulla 3-(3-(4-aryl-1-piperazinyl)-alkyl)-5,6,7,8-tetrahydro-s-triazolo-(4,3-a)pyridin eller -azepin

Country Status (22)

Country Link
US (2) US4252721A (ja)
JP (1) JPS5817757B2 (ja)
AT (1) AT374477B (ja)
AU (1) AU520788B2 (ja)
BG (2) BG40654A3 (ja)
CA (1) CA1104567A (ja)
CH (1) CH639847A5 (ja)
DE (1) DE2915318A1 (ja)
DK (1) DK148480C (ja)
FI (1) FI66378C (ja)
FR (1) FR2423221A1 (ja)
GB (1) GB2020269B (ja)
HU (1) HU179917B (ja)
IE (1) IE47965B1 (ja)
IL (1) IL56926A (ja)
IT (1) IT1094076B (ja)
NL (1) NL186635C (ja)
PL (1) PL116103B1 (ja)
PT (1) PT69502A (ja)
SE (1) SE437663B (ja)
SU (1) SU852174A3 (ja)
YU (1) YU41338B (ja)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
FR2580648B1 (fr) * 1985-04-17 1987-05-15 Adir Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4879294A (en) * 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
IT1224250B (it) * 1988-06-10 1990-09-26 Acraf Associzione del depiprazolo con la morfina
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US6187774B1 (en) * 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
WO2000018391A1 (fr) 1998-09-30 2000-04-06 Takeda Chemical Industries, Ltd. Medicaments qui ameliorent le pouvoir de vidange de la vessie
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
KR20040014600A (ko) * 2001-07-02 2004-02-14 산텐 세이야꾸 가부시키가이샤 알파1 수용체 차단약을 유효 성분으로 하는 시신경 보호제
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
AP2005003232A0 (en) 2002-08-19 2005-03-31 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
GEP20084406B (en) * 2003-05-30 2008-06-25 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
ATE412648T1 (de) * 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
EP1917257A1 (en) * 2005-08-10 2008-05-07 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
AU2007274724B2 (en) * 2006-07-14 2012-07-26 Ranbaxy Laboratories Limited Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
MX2021004708A (es) 2018-10-26 2021-11-03 Ocuphire Pharma Inc Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913454A (en) * 1956-11-23 1959-11-17 Schenley Ind Inc Certain cycloalkanotriazoles, process and intermediates
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3472853A (en) * 1967-05-29 1969-10-14 Sterling Drug Inc 1-((pyrido(2,1-c)-s-triazolyl)-lower-alkyl)-4-substituted- piperazines
JPS5070389A (ja) * 1973-10-30 1975-06-11

Also Published As

Publication number Publication date
IE790646L (en) 1979-10-18
GB2020269B (en) 1982-06-03
AT374477B (de) 1984-04-25
DK148480C (da) 1985-12-16
US4307095A (en) 1981-12-22
FI791217A (fi) 1979-10-19
DK148480B (da) 1985-07-15
PT69502A (en) 1979-05-01
YU41338B (en) 1987-02-28
BG40654A3 (en) 1987-01-15
AU520788B2 (en) 1982-02-25
DE2915318C2 (ja) 1990-12-13
DE2915318A1 (de) 1979-10-31
JPS5817757B2 (ja) 1983-04-09
US4252721A (en) 1981-02-24
YU86279A (en) 1983-12-31
DK156779A (da) 1979-10-19
CH639847A5 (it) 1983-12-15
BG61367B2 (bg) 1997-06-30
ATA292479A (de) 1983-09-15
NL7902489A (nl) 1979-10-22
PL116103B1 (en) 1981-05-30
SU852174A3 (ru) 1981-07-30
CA1104567A (en) 1981-07-07
SE437663B (sv) 1985-03-11
IE47965B1 (en) 1984-08-08
FR2423221A1 (fr) 1979-11-16
AU4583279A (en) 1979-10-25
FR2423221B1 (ja) 1983-03-18
IL56926A0 (en) 1979-05-31
HU179917B (en) 1983-01-28
JPS54157576A (en) 1979-12-12
IT7822421A0 (it) 1978-04-18
NL186635B (nl) 1990-08-16
GB2020269A (en) 1979-11-14
NL186635C (nl) 1991-01-16
IL56926A (en) 1983-09-30
SE7903327L (sv) 1979-10-19
IT1094076B (it) 1985-07-26
PL214969A1 (ja) 1980-03-10
FI66378B (fi) 1984-06-29

Similar Documents

Publication Publication Date Title
FI66378C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla 3-(3-(4-aryl-1-piperazinyl)-alkyl)-5,6,7,8-tetrahydro-s-triazolo-(4,3-a)pyridin eller -azepin
CN102341394B (zh) 聚(adp-核糖)聚合酶(parp)抑制剂
AU704955B2 (en) Use of CGMP-phosphodiesterase inhibitors to treat impotence
EP0828479B1 (en) Method of producing a solid dispersion of a poorly water soluble drug
FI73433B (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla imidazo/1,2-a/pyraziner.
US5563152A (en) Pyrrolo-pyridine derivatives
US5563150A (en) Pyrrolo-pyridine derivatives
IL32853A (en) 5,11-dihydro-6h-pyrido(2,3-b)-(1,4)benzodiazepine-6-ones substituted in 11-position and processes for the production thereof
CN104159899A (zh) 取代的三嗪衍生物及其作为可溶性鸟苷酸环化酶激发物的用途
CN103649093A (zh) 取代的咪唑并吡啶和咪唑并哒嗪及其用途
EP1858883A2 (en) Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors
JPH0641132A (ja) ピラジノインドール類
DK155524B (da) Kondenserede imidazolderivater og farmaceutiske praeparater indeholdende disse
EP0278161B1 (en) Ketone derivatives as medicaments for the treatment or prevention of the withdrawal syndrome
JP2002524460A (ja) 男性の勃起機能障害の処置のための５−ヘテロシクリルピラゾロ［４，３−ｄ］ピリミジン−７−オン
US3884920A (en) 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
JP2006517530A (ja) オキシトシン作動薬およびバソプレッシン拮抗薬としてのベンズアミド誘導体
KR19990067528A (ko) 카인산 신경 세포 독성 억제제 및 피리도티아진 유도체
US4325952A (en) Method of treating abstinence syndrome with cycloaklyltriazoles
JPH0368574A (ja) 薬学的に活性なアミノイミダゾピリジン
HU187922B (en) Process for preparing 3-/n,n-dimethyl-carbamoyl/-pyrazolo/1,5-a/-pyridine
US4307096A (en) Method of treating glaucoma with cycloalkyltriazoles
CA1267894A (en) 4-substituted 10-cyanomethylenethieno[4,3-e] benzoazepines
US3726977A (en) 2-NITRO-11-(1-PIPERAZINYL)-DIBENZ (b,f) (1,4) OXAZEPINES COMPOSITIONS IN THE TREATMENT OF DEPRESSION
KR820001450B1 (ko) 사이클로알킬 트리아졸의 제조방법

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: AZIENDE CHIMICHE RIUNITE ANGELINI